Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 3:15:1811-1817.
doi: 10.2147/DDDT.S240865. eCollection 2021.

The Application of Zonisamide to Patients Suffering from Dementia with Lewy Bodies: Emerging Clinical Data

Babak Tousi  1   2 , James B Leverenz  2
Affiliations
Review

The Application of Zonisamide to Patients Suffering from Dementia with Lewy Bodies: Emerging Clinical Data

Babak Tousi et al. Drug Des Devel Ther. .

Abstract

Zonisamide is an anti-epileptic medication with multiple mechanisms of action and a favorable safety profile. Zonisamide may interact with Lewy body dementia pathophysiology through a mechanism unrelated to its original indication. Zonisamide has shown efficacy as adjunct therapy for the management of motor symptoms in patients with Parkinson's disease (PD). Given that dementia with Lewy bodies (DLB) and PD are considered subtypes of a Lewy body disease spectrum, zonisamide was investigated for the treatment of parkinsonism in DLB. Phase II and phase III clinical trials were conducted in patients with DLB in Japan. In both studies, participants were randomized to receive 12 weeks of zonisamide 25 or 50 mg/day or placebo. Zonisamide significantly improved the Unified Parkinson's Disease Rating Scale Part III (UPDRS-III) without affecting the Mini-Mental State Examination (MMSE) or Neuropsychiatry Inventory-10 (NPI-10) scores at week 12. In 2018, zonisamide received Japanese regulatory approval for the additional indication of parkinsonism in DLB. This review discusses the emerging clinical data on zonisamide in the field of DLB.

Keywords: clinical trial; dementia with Lewy bodies; parkinsonism; zonisamide.

PubMed Disclaimer

Conflict of interest statement

Dr Babak Tousi reports being a consultant for Eisai and Biogen, and grants from the Alzheimer’s Drug Discovery Foundation, outside the submitted work. Dr James JB Leverenz reports grants from the NIH, during the conduct of the study; personal fees from Acadia, personal fees from Biogen, personal fees from Eisai, personal fees from Takeda, and grants from GE Healthcare, outside the submitted work. The authors report no other conflicts of interest in this work.

References

    1. McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88–100. doi: 10.1212/WNL.0000000000004058 - DOI - PMC - PubMed
    1. Tousi B. Diagnosis and management of cognitive and behavioral changes in dementia with Lewy bodies. Curr Treat Options Neurol. 2017;19(11). doi: 10.1007/s11940-017-0478-x - DOI - PubMed
    1. Goldman JG, Goetz CG, Brandabur M, Sanfilippo M, Stebbins GT. Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies. Mov Disord. 2008;23(15):2248–2250. doi: 10.1002/mds.22322 - DOI - PubMed
    1. Murata M, Odawara T, Hasegawa K, et al. Effect of zonisamide on parkinsonism in patients with dementia with Lewy bodies: a Phase 3 randomized clinical trial. Parkinsonism Relat Disord. 2020;76:91–97. doi: 10.1016/j.parkreldis.2019.12.005 - DOI - PubMed
    1. U.S. Food and Drug Administration. Zonisamide approvable labeling [Internet]. Approved labeling text; 2000. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2000/20789lbl.pdf. Accessed April20, 2021.

MeSH terms